

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US04/33735

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 31/70, 38/00; C07H 21/04; C07K 14/00

US CL : 514/2, 44; 536/23.1; 530/350

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/2, 44; 536/23.1; 530/350

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
Please See Continuation Sheet

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2003/0152926 A1 (MURRAY et al) 14 August 2003 (14.08.2003), especially paragraphs [0056]-[0057] and [0213]-[0269].	67-68
A	VERMA, I.M. and SOMIA, N. Gene Therapy--Promises, Problems and Prospects. Nature. September 1997, Vol. 389, pages 239-242.	1-119
A	PALU, G. et al. In Pursuit of New Developments for Gene Therapy of Human Diseases. Journal of Biotechnology. February 1999, Vol. 68, No. 1, pages 1-13.	1-119
A	LUO, D.L. and SALTZMAN, M.W. Synthetic DNA Delivery Systems. Nature Biotechnology. January 2000, Vol. 18, pages 33-37.	1-119
A	EDELSTEIN, M.L. et al. Gene Therapy Clinical Trials Worldwide 1989-2004--An Overview. The Journal of Gene Medicine. June 2004, Vol. 6, No. 6, pages 597-602.	1-119
A	STEWART, A.F.R. et al. Cloning of Human RTEF-1, a Transcriptional Enhancer Factor-1-Related Gene Preferentially Expressed in Skeletal Muscle: Evidence for an Ancient Multigene Family. Genomics. 1996, Vol. 36, pages 68-76.	1-119
A	UEYAMA, T. et al. Identification of the Functional Domain in the Transcription Factor RTEF-1 That Mediates alpha1-Adrenergic Signaling in Hypertrophied Cardiac Myocytes. The Journal of Biological Chemistry. June 2000, Vol. 275, No. 23, pages 17476-17480.	1-119



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier application or patent published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

06 September 2005 (06.09.2005)

Date of mailing of the international search report

28 OCT 2005

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Facsimile No. (703) 305-3230

Authorized officer

Jennifer Dunston

Telephone No. 571-272-0507

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US04/33735

Continuation of B. FIELDS SEARCHED Item 3:  
EAST, MEDLINE, EMBASE, BIOSIS, CAPLUS, CANCERLIT

search terms: related transcriptional enhancer factor-1, rtf-1, TEA domain family member 4, TEAD-4, TEF-3, EFTR-2, MGC9014, TCF13L1, hRTEF-1B, RTEF-1B, angiogenic, angiogenesis, hpoxic, hypoxia, HIF-1 alpha